E-LIB Suche - Ergebnisse für: Viardot, G.

1

Electrophysiological assessment methodology of sensory proc..:

Danjou, P ; Viardot, G ; Maurice, D...
https://research.rug.nl/en/publications/347a70fd-b700-4e03-b4b7-ab3d5bc7cf01. , 2019

Link: https://hdl.handle.net/1..

2

Alemtuzumab plus CHOP versus CHOP in elderly patients with ..:

Wulf, Gerald G ; Altmann, Bettina ; Ziepert, Marita...
boreal:264028. , 2021

Link: http://hdl.handle.net/20..

3

Alemtuzumab plus CHOP versus CHOP in elderly patients with ..:

Wulf, Gerald G ; Altmann, Bettina ; Ziepert, Marita...
https://research.rug.nl/en/publications/a1d0c479-d7ec-41d8-89e8-f1915a808445. , 2021

Link: https://hdl.handle.net/1..

4

Alemtuzumab plus CHOP versus CHOP in elderly patients with ..:

Wulf, Gerald G ; Altmann, Bettina ; Ziepert, Marita...
boreal:264028. , 2021

Link: http://hdl.handle.net/20..

5

Alemtuzumab plus CHOP versus CHOP in elderly patients with ..:

Wulf, Gerald G ; Altmann, Bettina ; Ziepert, Marita...
boreal:261897. , 2021

Link: http://hdl.handle.net/20..

6

Effects of targeted delivery of propionate to the human col..:

Chambers, Edward S ; Viardot, Alexander ; Psichas, Arianna...
http://eprints.gla.ac.uk/101681/1/101681.pdf. , 2015

Link: http://eprints.gla.ac.uk..

7

Improved outcome of adult Burkitt lymphoma/leukemia with ri..:

Hoelzer, Dieter ; Walewski, Jan ; Döhner, Hartmut...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC. , 2014

Link: http://www.ncbi.nlm.nih...

8

Follow-up of the GHSG HD16 trial of PET-guided treatment in..:

Fuchs, M ; Jacob, A.S ; Kaul, H...
http://edoc.mdc-berlin.de/23852/1/23852oa.pdf. , 2024

Link: http://edoc.mdc-berlin.d..

9

90-yttrium-ibritumomab tiuxetan as first-line treatment for..:

Rieger, K ; De Filippi, R ; Lindén, O...
http://edoc.mdc-berlin.de/21339/1/21339oa.pdf. , 2022

Link: http://edoc.mdc-berlin.d..

10

90-yttrium-ibritumomab tiuxetan as first-line treatment for..:

Rieger K ; De Filippi ; R. Lindén...
info:eu-repo/semantics/altIdentifier/wos/WOS:000754337100001. , 2022

Link: http://hdl.handle.net/11..

11

A phase II trial to evaluate the combination of pixantrone ..:

Hess, G ; Hüttmann, A ; Witzens-Harig, M...
http://edoc.mdc-berlin.de/21536/1/21536oa.pdf. , 2022

Link: http://edoc.mdc-berlin.d..

12

Open-label, phase 2 study of blinatumomab after frontline R..:

Katz, D.A ; Morris, J.D ; Chu, M.P...
https://eprints.whiterose.ac.uk/196253/1/Open%20label%20phase%202%20study%20of%20blinatumomab%20after%20frontline%20R%20chemotherapy%20in%20adults%20with%20newly%20diagnosed%20high%20risk%20DLBCL.pdf. , 2022

Link: https://eprints.whiteros..

13

S106: UBTF-ATXN7L3 GENE FUSION DUE TO 17Q21.31 DELETION DEF..:

L. Bastian ; A. Hartmann ; T. Beder...
http://journals.lww.com/10.1097/01.HS9.0000843320.74833.6a. , 2022

Link: https://doi.org/10.1097/..

14

The mTOR inhibitor temsirolimus added to rituximab combined..:

Witzens-Harig, M ; Viardot, A ; Keller, U...
http://edoc.mdc-berlin.de/20956/1/20956oa.pdf. , 2021

Link: http://edoc.mdc-berlin.d..

15

Phase I dose escalation study of BI 836826 (CD37 antibody) ..:

Kroschinsky, F ; Middeke, J.M ; Janz, M...
http://edoc.mdc-berlin.de/18813/1/18813oa.pdf. , 2020

Link: http://edoc.mdc-berlin.d..